Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Circulating miRNA" patented technology

Serum circulating miRNA-based echinococcosis detection markers and application thereof

The invention belongs to the technical field of biological detection, and particularly discloses a pair of echinococcosis detection markers based on serum circulating miRNA and application of the echinococcosis detection markers, the detection markers are a combination of miR-192-5p and miR-122-5p, the abundance of the miR-192-5p and the miR-122-5p in the serum of an echinococcosis patient is remarkably reduced, the miR-192-5p and the miR-122-5p are in negative correlation with echinococcosis infection, and the threshold values are 0.35 and 0.04 respectively. During detection, the relative expression level (taking caenorhabditis elegans miR-39-3p as an external reference) of caenorhabditis elegans miR-39-3p in serum is determined through qPCR, and the positive and negative properties are judged according to a threshold value; the area under the ROC curve of the marker combination reaches 0.97, and a double-blind test shows that the positive rate and the negative rate of human and mouse serum detection are 100%. The method solves the problems of missed diagnosis and misdiagnosis in existing echinococcosis detection, can be used for preparing a detection kit, realizes accurate detection, curative effect evaluation and prognosis management of echinococcosis, and has extremely high clinical application value.
Owner:ZHEJIANG FORESTRY UNIVERSITY +3

A miRNA-BASES METHOD FOR LUNG CANCER DETECTION

PCT designated stageWO2026114962A1Microbiological testing/measurementCancer researchCirculating miRNA
The present invention describes a method for diagnosing lung cancer in a subject by detecting specific circulating miRNAs ("c-miR signature") in a biological sample obtained from that subject. Such c-miR signature provides an indication and a prognosis of lung cancer in place of or in addition to alternative known methods, including, but not limited to, low-dose computed tomography (LDCT).
Owner:FONDAZIONE DI RELIGIONE E CULTO CASA SOLLIEVO DELLA SOFFERENZA IRCCS - OPERA DI SAN PIO DA PIETRELCINA